-
公开(公告)号:WO2010006059A8
公开(公告)日:2010-09-02
申请号:PCT/US2009049953
申请日:2009-07-08
Applicant: ABBOTT LAB , GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING
Inventor: GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING
IPC: A61K39/395
CPC classification number: C07K16/18 , A61K31/405 , A61K31/573 , A61K39/39533 , A61K2039/505 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
Abstract translation: 本发明包括前列腺素E2(PGE2)结合蛋白。 本发明涉及野生型,嵌合,CDR移植和人源化的抗体。 优选的抗体对前列腺素E2具有高亲和力并且在体外和体内中和前列腺素E2的活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性,例如,在患有前列腺素E2活性是有害的病症的人类受试者中。
-
公开(公告)号:SG192496A1
公开(公告)日:2013-08-30
申请号:SG2013052923
申请日:2009-07-08
Applicant: ABBOTT LAB
Inventor: GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING
Abstract: PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF AbstractThe present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E, activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Figure I
-
公开(公告)号:CA2728909A1
公开(公告)日:2010-01-14
申请号:CA2728909
申请日:2009-07-08
Applicant: ABBOTT LAB
Inventor: GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING
IPC: C07K16/18 , A61K39/395 , C07K16/46 , C12N15/13
Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
-
公开(公告)号:BRPI0915825A2
公开(公告)日:2015-11-03
申请号:BRPI0915825
申请日:2009-07-08
Applicant: ABBOTT LAB
Inventor: MURTAZA ANWAR , HUTCHINS CHARLES W , HSIEH CHUNG-MING , TARCSA EDIT , BELANGER EILEEN , SHEN JIANWEI , GU JIJIE , HARRIS MARIA C , ZHU RONG-RONG , STINE WILLIAM B
IPC: A61K39/395
-
公开(公告)号:MX2010014573A
公开(公告)日:2011-09-16
申请号:MX2010014573
申请日:2010-12-21
Applicant: ABBOTT LAB
Inventor: HUTCHINS CHARLES W , HSIEH CHUNG-MING , GU JIJIE , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B
IPC: A61K39/395
Abstract: La presente invención abarcar proteínas de unión de prostaglandina E2 (PGE2). La invención se refiere a anticuerpos que son de tipo silvestre, quiméricos, de CDR injertada y humanizados. Los anticuerpos preferidos tienen alta afinidad para prostaglandina E2 y neutralizan la actividad de prostaglandina E2 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa, o una porción de unión a antígeno del mismo. También se proporcionan métodos para hacer y métodos para utilizar los anticuerpos de la invención. Los anticuerpos, o porciones de unión a antígeno, de la invención son útiles para detectar prostaglandina E2 y para inhibir la actividad de prostaglandina E2, por ejemplo, en un ser humano que sufre de un trastorno en donde la actividad de prostaglandina E2 es dañina.
-
-
-
-